Introduction {#s1}
============

It is well established that antipsychotics are effective in the majority of patients with schizophrenia ([@CIT0040]). However, from one-fifth to one-third of the overall number of subjects undergoing the treatment demonstrate only partial, if any, improvement despite the antipsychotic treatment, adequate in terms of dosage and duration ([@CIT0050]). Treatment of these patients remains a major challenge, causing a serious burden for patients and their families and incurring high public health costs ([@CIT0032]).

Clozapine, the prototypic "atypical" antipsychotic (presently referred to most often as second-generation antipsychotic \[SGA\]), is proven to be effective in a significant proportion of the patients who do not respond to other antipsychotic medications ([@CIT0035]; [@CIT0005]; [@CIT0036]). The mechanisms of the superior efficacy of clozapine are still obscure and are usually attributed to the drug's complex receptor profile ([@CIT0046]). However, some serious, sometimes life-threatening, adverse effects of clozapine (eg, weight gain, epileptic seizures, ileus, or agranulocytosis) limit its use in clinical practice ([@CIT0035]). This calls for the search of new treatment strategies, including psychopharmacological approaches.

Indeed, a number of medications have been studied as adjuncts to antipsychotics with a goal to improve positive, negative, affective, or cognitive symptoms of schizophrenia resistant to antipsychotic medication alone. These pharmacological agents include lithium, anticonvulsants, antiinflammatory and glutamatergic drugs, sex hormones, cholinesterase and phosphodiesterase inhibitors, and various antidepressants ([@CIT0066]; [@CIT0040]; [@CIT0078]).

Although the use of antidepressants added to antipsychotics in schizophrenia has been a subject of intensive research during the recent decades, the evidence regarding their efficacy still remains conflicting ([@CIT0030]). Nevertheless, antidepressants tend to be routinely used by clinicians ([@CIT0085]; [@CIT0029]). For instance, in the Clinical Trials of Intervention Effectiveness study, about one-third of the participants were receiving an antidepressant at the study baseline ([@CIT0011]). Thus, there seems to exist a gap between the wide use of antidepressants in clinical practice and the research evidence supporting this approach.

The present study aimed to review the published randomized controlled trials (RCTs) with antidepressants added to antipsychotics in the treatment of schizophrenia.

Methods {#s2}
=======

Published RCTs assessing the efficacy of adjunctive antidepressants in schizophrenia were searched for in the PUBMED, PsycINFO, and PsycLIT databases from January 1960 to December 2013, using the following keywords: "schizophrenia" AND "antidepressant" OR "tricyclic antidepressant" OR "monoaminoxidase inhibitor" OR "selective serotonin reuptake inhibitor" OR "norepinephrine reuptake inhibitor", as well as "schizophrenia" AND "amitriptyline" OR "imipramine" OR "clomipramine" OR "fluoxetine" OR "fluvoxamine" OR "sertraline" OR "paroxetine" OR "citalopram" OR "escitalopram" OR "venlafaxine" OR "duloxetine" OR "bupropion" OR "milnacipran" OR "reboxetine" OR "trazodone" OR "nefazodon" OR "mianserin" OR "mirtazapine" OR "vortioxetine" OR "vilazodone" OR "agomelatine", as well as "schizophrenia" AND "double-blind" AND "augmentation", as well as "schizophrenia" AND "double-blind" AND "adjunctive." To obtain further data, hand searches of references in published review articles as well as cross-referencing were used.

All citations were reviewed using the following parameters: baseline clinical characteristics of patients and their antipsychotic treatment, dose of the add-on antidepressant, duration of the trial, number of participants, efficacy measures, and outcome.

Results {#s3}
=======

We were able to locate a total of 36 RCTs (reported in 41 journal publications) including 1582 subjects with a diagnosis of schizophrenia or schizoaffective disorder ([Table 1](#T1){ref-type="table"}). All included trials employed head-to-head, parallel group, double-blind design comparing the efficacy of an add-on antidepressant vs add-on placebo with the exception of trials by [@CIT0024] and [@CIT0074] that employed a crossover design. The vast majority of trials were small with the number of subjects ranging from 14 to 53. This number was exceeded only in the trial by Salokangas and coauthors (1996) (n=90). The duration of the trials ranged from 1 to 24 weeks. In 18 trials, an antidepressant was added to first-generation antipsychotics (FGAs), in 11 trials to SGAs, and in the rest of the trials to various antipsychotics.

###### 

Antidepressants as Add-On Treatment in Schizophrenia: Randomized Placebo-Controlled Trials

Table 1a. Antidepressants in Treatment of Negative and Positive Symptoms

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **AntidepressantGroup**              **Author(s**)        **Year**       **Antidepressant**   **Dose,**\                   **Antipsychotic**       **N**   **Duration,**\     **Efficacy**\                                                                                                                     **Outcome**
                                                                                                **Mg**                                                       **wk**             **Measures**                                                                                                                      
  ------------------------------------ -------------------- -------------- -------------------- ---------------------------- ----------------------- ------- ------------------ --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  TCA                                  Collins and Dungas   1967           Amitryptiline        n/r                          Perphenazine            87      12                 Wing scale                                                                                                                        Improvement in amitriptyline group.

  Waehrens and\                        1980                 Maprotiline    n/r                  Various FGAs                 20                      16      n/r                No between group differences.                                                                                                     
  Gerlach                                                                                                                                                                                                                                                                                                         

  Siris et al.                         1991                 Imipramine     n/r                  Depot FGAs                   14                      24      n/r                Improvement in negative symptoms in imipramine group.                                                                             

  SSRI                                 Spina et al.         1994           Fluoxetine           20                           Various FGAs            34      12                 SANS, SAPS                                                                                                                        Improvement on the SANS in fluoxetine group. No change on the SAPS in either group.

  Goff et al.                          1995                 Fluoxetine     20                   Depot FGAs                   41                      6       BPRS               Greater improvement in fluoxetine group on the BPRS negative subscale. No change on the BPRS positive subscale in either group.   

  Buchanan et al.                      1996                 Fluoxetine     20                   Clozapine                    33                      8       SANS               No change in either group.                                                                                                        

  Arango et al.                        2000                 Fluoxetine     20--40               Various FGAs                 32                      8       BPRS, SANS         No change in either group.                                                                                                        

  Poyurovski et al.\*                  2002                 Fluoxetine     20                   Olanzapine                   30                      8       SAPS, SANS         Greater reduction on the SAPS in placebo group than in fluoxetine group.                                                          

  Bustillo et al.\*                    2003                 Fluoxetine     60                   Olanzapine                   31                      8       PANSS              No change in either group.                                                                                                        

  Silver and Nassar                    1992                 Fluvoxamine    50--100              Various FGAs                 30                      7       SANS, SAPS         Improvement on the SANS in fluvoxamine group. No change on the SAPS in either group.                                              

  Silver et al.                        2000                 Fluvoxamine    50--100              Various FGAs                 53                      6       SANS, SAPS         Improvement on the SANS in fluvoxamine group. No change on the SAPS in either group.                                              

  Lee et al.                           1998                 Sertraline     50                   Haloperidol                  36                      8       PANSS              No change in either group.                                                                                                        

  Mulholand et al.\*                   2003                 Sertraline     50                   Variopus FGAs, risperidone   26                      8       BPRS, SANS         No change in either group.                                                                                                        

  Salokangas et al.                    1996                 Citalopram     20--40               Various FGAs                 90                      12      PANSS              Decrease on the PANSS total scale in both groups, no between group differences.                                                   

  Friedman et al.                      2005                 Citalopram     40                   Various SGAs                 19                      24      PANSS              No change in either group.                                                                                                        

  Iancu et al.                         2010                 Escitalopram   20                   Various FGAs and SGAs        38                      10      PANSS, SANS, CGI   No change in either group.                                                                                                        

  Jockers et al.                       2005                 Paroxetine     30                   Various FGAs and SGAs        29                      12      PANSS              Improvement in paroxetine group on the PANSS negative subscale.                                                                   

  NRI                                  Schutz and Berk      2001           Reboxetine           8                            Haloperidol             30      8                  PANSS                                                                                                                             No change in either group.

  Poyurovski et al.\*                  2003                 Reboxetine     4                    Olanzapine                   26                      6       SANS, SAPS         No change in either group.                                                                                                        

  SNRI                                 Mico et al.          2011           Duloxetine           60                           Clozapine               33      16                 BPRS,\                                                                                                                            Improvement on the BPRS, PANSS negative, PANSS general and PANSS total (sub)scales in duloxetine group.
                                                                                                                                                                                PANSS                                                                                                                             

  NDRI                                 Evins et al.\*       2005           Bupropion            300                          Clozapine, FGAs, SGAs   53      12                 SANS                                                                                                                              No change in either group.

  Weiner et al.\*                      2012                 Bupropion      300                  Clozapine, FGAs, SGAs        32                      12      n/a                No change in either group                                                                                                         

  Receptor- blocking antidepressants   Decina et al.        1994           Trazodone            n/r                          n/r                     47      6                  BPRS, SANS                                                                                                                        Improvement on the BPRS and SANS in trazodone group.

                                       Hayashi et al.       1997           Trazodone            50--200                      n/r                     39      5                  BPRS, SANS                                                                                                                        Improvement on the BPRS negative subscale in trazodone group.

                                       Stryjer et al.\*     2010           Trazodone            100                          n/r                     13      1                  PANSS                                                                                                                             No change in either group.

                                       Shiloh et al.        2002           Mianserin            30                           Various FGAs            18      6                  BPRS, SAPS, SANS                                                                                                                  Improvement on the BPRS in mianserin group.

                                       Hayashi et al.       1997           Mianserin            20--60                       n/r                     39      5                  BPRS, SANS                                                                                                                        Improvement on the BPRS and SANS in mianserin group.

                                       Poyurovski et al.    2003           Mianserin            15                           Various FGAs            30      4                  SAPS, SANS                                                                                                                        No change in either group.

                                       Berk et al.          2001           Mirtazapine          30                           Haloperidol             30      6                  PANSS                                                                                                                             Improvement on the PANSS negative subscale in mirtazapine group.

                                       Zoccali et al.       2004           Mirtazapine          30                           Clozapine               24      8                  SANS, SAPS, BPRS                                                                                                                  Improvement on the SANS and BPRS general subscale in mirtazapine group.

                                       Joffe et al.         2009           Mirtazapine          30                           Various FGAs            39      6                  PANSS                                                                                                                             Improvement on the PANSS total and all PANSS subscales in mirtazapine group.

                                       Berk et al.          2009           Mirtazapine          30                           Various SGAs            40      6                  PANSS                                                                                                                             No change in either group.

                                       Abbasi et al.        2010           Mirtazapine          30                           Risperidone             40      8                  PANSS                                                                                                                             Improvement on the PANSS negative and PANSS total in mirtazapine group.

                                       Cho et al.           2011           Mirtazapine          n/r                          Risperidone             21      8                  PANSS,\                                                                                                                           Improvement on the PANSS negative and SANS in mirtazapine group.
                                                                                                                                                                                SANS                                                                                                                              

                                       Caforio et al.       2013           Mirtazapine          30                           Olanzapine              28      8                  PANSS                                                                                                                             Improvement on PANSS negative subscale in mirtazapine group.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antidepressants in Treatment of Depressive Symptoms

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antidepressant Group**            **Author(s**)     **Year**       **Antidepressant**   **Dose,**\                  **Antipsychotic**           **N**   **Duration,**\                  **Efficacy**\                                        **Outcome**
                                                                                            **mg**                                                          **wk**                          **Measures**                                         
  ----------------------------------- ----------------- -------------- -------------------- --------------------------- --------------------------- ------- ------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------
  TCA                                 Siris et al.      2000           Imipramine           n/r                         Flufenazine decanoate       70      6                               HDRS, SADS                                           Improvement in imipramine group.

  SSRIs                               Spina et al.      1994           Fluoxetine           20                          Various FGAs                34      12                              HDRS                                                 Improvement in fluoxetine group.

  Buchanan et al.                     1996              Fluoxetine     20                   Clozapine                   33                          8       n/r                             No change in either group.                           

  Arango et al.                       2000              Fluoxetine     20--40               Various FGAs                32                          8       HDRS                            No change in either group.                           

  Bustillo et al.\*                   2003              Fluoxetine     60                   Olanzapine                  31                          8       HDRS                            No change in either group.                           

  Mulholand et al.                    2003              Sertraline     50                   Various FGAs, risperidone   26                          8       HDRS, BDI                       Improvement on both measures in sertraline group.    

  Jockers et al.                      2005              Paroxetine     30                   Various FGAs and SGAs       29                          12      HDRS                            No change in either group.                           

  Iancu et al.                        2010              Escitalopram   20                   Various FGAs and SGAs       38                          10      HDRS                            No change in either group.                           

  NRI                                 Schutz and Berk   2001           Reboxetine           8                           Haloperidol                 30      8                               HDRS                                                 No change in either group.

  Poyurovski et al.\*                 2003              Reboxetine     4                    Olanzapine                  26                          6       HDRS                            Improvement in reboxetine group.                     

  SNRI                                Mico et al.       2011           Duloxetine           60                          Clozapine                   33      16                              CDSS                                                 Improvement in duloxetine group.

  NDRI                                Dufresne et al.   1988           Bupropion            300                         FGAs                        38      12                              BPRS                                                 Reduction of depressive symptoms in placebo group.

                                      Evins et al.\*    2005           Bupropion            300                         Clozapine, FGAs, SGAs       53      12                              HDRS                                                 No change in either group.

  Receptor-blocking antidepressants   Shiloh et al.     2002           Mianserin            30                          Haloperidol, perphenazine   18      6                               HDRS                                                 Improvement on the HDRS in both groups with no between-group difference.

  Poyurovski et al.                   2003              Mianserin      15                   Various FGAs                30                          4       HDRS                            No change in either group.                           

  Stryjer et al.\*                    2010              Trazodone      100                  n/r                         13                          1       HDRS                            No change in either group.                           

  Zoccali et al.                      2004              Mirtazapine    30                   Clozapine                   24                          8       BPRS (depressive factor)        No change in either group.                           

  Berk et al.                         2009              Mirtazapine    30                   Various SGAs                40                          6       CDSS, HDRS                      No change in either group.                           

  Terevnikov et al.                   2011              Mirtazapine    30                   Various FGAs                41                          6       CDSS, PANSS (depression item)   Improvement on both measures in mirtazapine group.   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antidepressants in Treatment of Extrapyramidal Symptoms

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antidepressant Group**            **Author(s**)     **Year**       **Antidepressant**   **Dose,**\                  **Antipsychotic**   **N**   **Duration,**\   **Efficacy Measures**                                                                                           **Outcome**
                                                                                            **mg**                                                  **wk**                                                                                                                           
  ----------------------------------- ----------------- -------------- -------------------- --------------------------- ------------------- ------- ---------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------
  SSRIs                               Goff et al.       1995           Fluoxetine           20                          Depot FGAs          41      6                n/r                                                                                                             No change in either group.

  Arango et al.                       2000              Fluoxetine     20--40               Various FGAs                32                  8       MIMS             No change in either group.                                                                                      

  Bustillo et al.\*                   2003              Fluoxetine     60                   Olanzapine                  31                  8       SAS, BAS, AIMS   No change in either group.                                                                                      

  Lee et al.                          1998              Sertraline     50                   Haloperidol                 36                  8       SAS              No change in either group.                                                                                      

  Mulholand et al.\*                  2003              Sertraline     50                   Various FGAs, risperidone   26                  8       ESRS, BAS        No change in sertraline group, worsening of ESRS scores in placebo group.                                       

  Jockers et al.                      2005              Paroxetine     30                   Various FGAs and SGAs       29                  12      SAS, BAS, AIMS   No change in either group.                                                                                      

  Iancu et al.                        2010              Escitalopram   20                   Various FGAs and SGAs       38                  10      AIMS             No change in either group.                                                                                      

  NRI                                 Schutz and Berk   2001           Reboxetine           8                           Haloperidol         30      8                SAS                                                                                                             No change in either group.

  Poyurovski et al.\*                 2003              Reboxetine     4                    Olanzapine                  26                  6       BAS, SAS         SAS scores decreased in both groups with no between-group difference in observed change.                        

  Receptor-blocking antidepressants   Hayashi et al.    1997           Trazodone            50--200                     n/r                 39      5                AIMS                                                                                                            Improvement in trazodone group.

  Stryjer et al.                      2010              Trazodone      100                  n/r                         13                  1       SAS, BAS         Between group differences on the BAS scores in favour of trazodone. No changes on SAS scores in either group.   

  Hayashi et al.                      1997              Mianserin      20--60               n/r                         39                  5       AIMS             No change in either group.                                                                                      

  Poyurovski et al.                   2003              Mianserin      15                   Various FGAs                30                  4       BAS, SAS, AIMS   No change in either group.                                                                                      

  Berk et al.                         2001              Mirtazapine    30                   Haloperidol                 30                  6       SAS              No change in either group.                                                                                      

  Joffe et al.\*                      2009              Mirtazapine    30                   Various FGAs                39                  6       SAS              Improvement on the SAS scores in mirtazapine group. No between group differences.                               

  Berk et al.                         2009              Mirtazapine    30                   Various SGAs                40                  6       SAS              No change in either group.                                                                                      

  Abbasi et al.                       2010              Mirtazapine    30                   Risperidone                 40                  8       ESRS             No change in either group.                                                                                      

  Lee et al.                          2011              Mirtazapine    15--30               Risperidone                 21                  8       SAS, BAS         No between group differences on either measure.                                                                 

  Wynchank and Berk                   2003              Nefazodone     100                  Haloperidol                 49                  1       SAS, BAS, AIMS   Improvement on the SAS in nefazodone group. No changes on the BAS or AIMS in either group.                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antidepressants in Treatment of Cognitive Symptoms

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author(s**)         **Year**   **Antidepressant**   **Dose,**\   **Antipsychotic**       **N**   **Duration,**\   **Neurocognitive parameters**                                                                                                      **Outcome**
                                                        **mg**                                       **wk**                                                                                                                                              
  --------------------- ---------- -------------------- ------------ ----------------------- ------- ---------------- ---------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Friedman et al.\*     2005       Citalopram           40           Various SGAs            19      24               Attention, working\                                                                                                                No change in either group.
                                                                                                                      memory, executive function                                                                                                         

  Evins et al.\*        2005       Bupropion            300          Clozapine, FGAs, SGAs   53      4                Attention, verbal learning and memory, working memory, executive function                                                          Improvement in attention tests in the bupropion group.

  Poyurovski et al.\*   2003       Mianserin            15           Various FGAs            30      4                Learning, memory, sustained attention, executive function                                                                          Between group differences in favour of mianserin on memory and learning tests.

  Stenberg et al.\*     2010       Mirtazapine          30           Various FGAs            37      6                Visuo-spatial functions, verbal and visual memory, executive functions, verbal fluency, and general mental and psychomotor speed   Between group differences in favour of mirtazapine in visual-spatial ability and general mental speed/attentional control.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AIMS, Abnormal Involuntary Movements Scale; BAS, Barnes Akathisia Scale; BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; CGI, Clinical Global Impression scale; ESRS, Extrapyramidal Symptom Rating Scale; FGA, first-generation antipsychotic; HDRS, Hamilton Rating Scale for Depression; MADRS, Montgomery--Åsberg Depression Rating Scale; MIMS, Maryland Psychiatric Research Center Involuntary Movement Scale; NDRI, noradrenaline and dopamine reuptake inhibitor; n/r, not reported; NRI, selective noradrenaline reuptake inhibitor; PANSS, Positive and Negative Syndrome Scale; SADS, Scale for the Assessment of Depression and Schizophrenia; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; SAS, Simpson-Angus Scale; SGA, second-generation antipsychotic; SNRI, selective serotonin and noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

^\*^ Studies in which the efficacy measure was a subject for secondary analysis.

In all trials, the efficacy measures---Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms, Scale for the Assessment of Positive Symptoms, Clinical Global Impression Scale, and the Wing's scale---were used prospectively from baseline to endpoint. In only 14 studies were a priori defined minimum cut-off points on the Brief Psychiatric Rating Scale or PANSS scales used as an inclusion criterion, while in the others the subjects were vaguely defined to be "symptomatic" or "suffering from positive or negative symptoms" despite adequate antipsychotic treatment. Twenty-two trials included clinically stable subjects. Furthermore, in 21 trials, a thoroughly defined period of an unchanged antipsychotic treatment was required prior to participation in the study. This period varied from 1 week to 6 months. Presence of the current significant depressive symptoms served as an exclusion criterion in 12 trials. Of the others, 15 trials used depression rating scales as an outcome measure: the Hamilton Rating Scale for Depression, Calgary Depression Scale for Schizophrenia, Beck Depression Inventory, or Montgomery--Åsberg Depression Rating Scale. Extrapyramidal symptom rating scales---the Simpson-Angus Scale for extrapyramidal effects, the Abnormal Involuntary Movements Scale, and the Barnes Akathisia Scale---were used in 17 trials. Noteworthy, 5 trials were initially designed to investigate the effect of antidepressant add-on treatment of antipsychotic-induced weight gain ([@CIT0054]; [@CIT0009]; [@CIT0055]) or smoking cessation ([@CIT0021]a; [@CIT0081]). These trials also utilized psychopathology rating scales (PANSS, Scale for the Assessment of Negative Symptoms, Scale for the Assessment of Positive Symptoms, Hamilton Rating Scale for Depression) and were thus included into this review.

The add-on antidepressant and add-on placebo groups did not generally differ significantly in baseline clinical characteristics. In only one trial ([@CIT0034]) the add-on antidepressant group had somewhat higher PANSS total scores at baseline.

Add-On Antidepressants in the Treatment of Positive and Negative Symptoms of Schizophrenia {#s4}
------------------------------------------------------------------------------------------

The included RCTs are presented in [Table 1](#T1){ref-type="table"}. In regard to the negative symptoms, trials with the tricyclic antidepressants (TCAs) yielded mainly positive results, but the studies were relatively old ([@CIT0013]; [@CIT0080]; [@CIT0068]). The outcomes of the SSRI trials as a group were controversial. Of 6 studies with fluoxetine, only 2 were positive ([@CIT0070]; [@CIT0025]). While both studies with fluvoxamine ([@CIT0064]; [@CIT0065]) and the only study with paroxetine ([@CIT0033]) were positive, adjunctive citalopram ([@CIT0061]; [@CIT0024]), escitalopram ([@CIT0031]), and sertraline ([@CIT0037]; [@CIT0049]) failed to demonstrate any benefits in any of the published trials. Likewise, both trials with the selective noradrenaline reuptake inhibitor reboxetine were negative ([@CIT0062]; [@CIT0055]). Conversely, in the only trial with the selective serotonin and noradrenaline reuptake inhibitor duloxetine, the active medication outperformed placebo on the PANSS negative subscale ([@CIT0048]). Bupropion, a noradrenaline and dopamine reuptake inhibitor, demonstrated a trend toward improvement in negative symptoms that did not reach statistical significance in one RCT ([@CIT0021]a). In another RCT ([@CIT0081]), bupropion did not override placebo (for review, see [@CIT0020]). For mianserine, trazodon, nefazodon, and mirtazapine (further referred to as receptor-blocking antidepressants, since they affect serotonin 5HT2 receptors rather than monoamine transporters, as opposed to the vast majority of existing antidepressants that are monoamine transporter blockers), most of the RCTs (8 of 12) were positive: 2 of 3 studies with trazodone ([@CIT0016]; [@CIT0028]), 1 of 3 studies with mianserin ([@CIT0028]), and 6 of 7 studies with mirtazapine ([@CIT0006]; [@CIT0087]; [@CIT0034]; [@CIT0001]; [@CIT0012]; [@CIT0010]).

In only one study, an add-on antidepressant (mirtazapine) improved the positive symptoms of schizophrenia ([@CIT0034]). Noteworthy, a trend (*P*=.07) in favor of an antidepressant was also found in 1of 3 RCTs with mianserin ([@CIT0063]).

No add-on RCTs with novel antidepressants agomelatine, vortioxetine, or vilazodone are yet available.

Add-On Antidepressants in the Treatment of Depressive Symptoms of Schizophrenia {#s5}
-------------------------------------------------------------------------------

Antidepressant augmentation was found to be effective in the treatment of depressive symptoms of schizophrenia in only a small number of studies. These included imipramine ([@CIT0067]), fluoxetine ([@CIT0070]), sertraline ([@CIT0049]), citalopram ([@CIT0086]), reboxetine ([@CIT0055]), duloxetine ([@CIT0048]), and mirtazapine ([@CIT0073]). The majority of the identified studies, however---3 RCTs with fluoxetine ([@CIT0008]; [@CIT0004]; [@CIT0009]), 2 RCTs with mirtazapine ([@CIT0087]; [@CIT0007]), and one RCT for each with paroxetine ([@CIT0033]), reboxetine ([@CIT0062]), mianserin ([@CIT0056]), and trazodone ([@CIT0074])---generated negative results. Also both RCTs with bupropion ([@CIT0018]; [@CIT0021]a) were negative (though a desired trend was observed in the latter one. For review, see [@CIT0020]).

Add-On Antidepressants in the Treatment of Extrapyramidal Side-Effects of Antipsychotics {#s6}
----------------------------------------------------------------------------------------

All trials with the SSRIs ([@CIT0025]; [@CIT0037]; [@CIT0004]; [@CIT0009]; [@CIT0049]; [@CIT0033]) demonstrated negative outcomes, as did both trials with reboxetine ([@CIT0062]; [@CIT0055]). Of the receptor-blocking antidepressants, mianserin failed to show superiority over placebo in both conducted trials ([@CIT0028]; [@CIT0056]), while both trials with trazodone ([@CIT0028]; [@CIT0074]) and the only trial with nefazodone ([@CIT0083]) were positive. Mirtazapine was superior to placebo in alleviating antipsychotic-induced extrapyramidal symptoms (EPS) in only 1 of the 5 conducted trials ([@CIT0034]).

Add-On Antidepressants in the Treatment of Cognitive Dysfunction in Schizophrenia {#s7}
---------------------------------------------------------------------------------

Of the SSRIs, the only available study (one with citalopram) did not reveal any improvement in cognitive functions ([@CIT0024]). Of the receptor-blocking antidepressants, mianserin added to FGAs showed beneficial effects on memory and learning with no between-group differences for executive functions ([@CIT0056]). Mirtazapine outperformed placebo in between-group comparisons for visual-spatial ability and general mental speed/attentional control but not for other neurocognitive functions ([@CIT0072]). Evins and collaborators (2005b) reported improvement in attention tests in an RCT with adjunctive bupropion, a noradrenaline and dopamine reuptake inhibitor.

Results {#s8}
=======

The effects of different groups of add-on antidepressants on major psychopathology domains of schizophrenia are summarized in [Table 2](#T2){ref-type="table"}. The vast majority of publications reported no favorable effect of add-on antidepressants on the schizophrenia symptom domains. The only exception was the group of the receptor blocking antidepressants, with 9 studies reporting desirable results for negative symptoms (vs 3 studies that did not show benefits for this symptom domain) and, correspondingly, 2 studies (vs 1 study) for cognitive deficits.

###### 

Effects of Different Groups of Add-On Antidepressants on Major Psychopathology Domains of Schizophrenia: Summary of Randomized Controlled Trials (RCTs)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **AntidepressantGroup**             **Effect**                          **Negative Symptoms**                         **Positive Symptoms**   **Depressive symptoms**       Extrapyramidal symptoms   Cognitive symptoms
  ----------------------------------- ----------------------------------- --------------------------------------------- ----------------------- ----------------------------- ------------------------- --------------------
  TCA                                 \+                                  1,4 (n=101)                                   n/a                     4 (n=14)                      n/a                       n/a

  0                                   2 (n=20)                            n/a                                           n/a                     n/a                           n/a                       

  SSRI                                \+                                  5,7,8,15,29 (n=187)                           n/a                     7,21 (n=60)                   n/a                       n/a

  0                                   9,10,13,14,18,20,21,28,35 (n=335)   5,7,8,9,10,13,14,15,18,20,21,28,2 9 (n=489)   9,14,20,29,35\          8,13,14,20,21,29,35 (n=233)   28 (n=19)                 
                                                                                                                        (n=163)                                                                         

  NRI                                 \+                                  n/a                                           n/a                     22                            n/a                       n/a

  0                                   17,22 (n=56)                        17,22 (n=56)                                  17 (n=30)               17,22 (n=56)                  n/a                       

  SNRI                                \+                                  38 (n=33)                                     n/a                     38 (n=33)                     n/a                       n/a

  0                                   n/a                                 38 (n=33)                                     n/a                     n/a                           n/a                       

  NDRI                                \+                                  n/a                                           n/a                     n/a                           n/a                       27 (n=53)

  0                                   26, 40 (n=85)                       26, 40 (n=85)                                 3, 26 (n=91)            n/a                           n/a                       

  Receptor blocking antidepressants   \+                                  6,11,12,16,19,25,31,32,36,41 (n=325)          31 (n=39)               39 (n=41)                     11,24,31,34 (n=140)       23,33 (n=67)

  0                                   23,30,34 (n=83)                     6,11,12,16,19,23,25,30,32,34,36 (n=341)       19,23,25,30,34\         12,16,23,30,32,37\            n/a                       
                                                                                                                        (n=125)                 (n=200)                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: n/a, no published RCTs found; NDRI, noradrenaline and dopamine reuptake inhibitor; NRI, selective noradrenaline reuptake inhibitor; SNRI, serotonin and noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; +, result favoring antidepressant over placebo; 0, no difference between antidepressant and placebo.

Worsening of schizophrenia symptoms was not reported in any of the studies. The numbers in the syndrome columns refer to the index number of the RCT listed below. The list is arranged in chronological order, meaning that the larger the number the more recent (and often methodologically more reliable) is the corresponding study. The positive (+) and negative (0) studies ratio depicts roughly the balance of pro et contra evidence for each antidepressant group in each symptom domain. (The studies are not weighted in terms of methodological quality or number of participants and should be thus taken with caution).

No add-on RCTs with new novel antidepressants vortioxetine, vilazodone, or agomelatine could be located.

Adverse Effects Due to Adjunctive Antidepressants in Schizophrenia {#s9}
------------------------------------------------------------------

The majority of the included studies reported overall good tolerability of antidepressant-antipsychotic combinations. [@CIT0070] observed, however, more common adverse effects in patients receiving add-on fluoxetine compared with those receiving an antipsychotic alone. Noteworthy, no RCTs reported worsened psychosis due to adjunctive antidepressants.

Discussion {#s10}
==========

We were able to identify 36 RCTs on combinations of antidepressants with an ongoing antipsychotic treatment published in the period from 1968 to 2013. The RCTs comprised the majority of the existing antidepressants and aimed to study their efficacy for the main clinical domains of schizophrenia. To summarize, the existing evidence regarding the efficacy of antidepressants in the treatment of schizophrenia is mixed.

The methodological quality of the studies varied. Overall, the later RCTs reported more precisely than the earlier ones the outcome criteria, the dosages of the study drugs, the clinical scales used, the patient population's clinical and demographic characteristics, etc. This progress of the clinical study methodology advocates, in general, giving more weight to the most recent studies. Nevertheless, both old and recent RCTs have a number of restrictions. Almost all of them comprise small patient samples. Many publications express secondary analysis from the studies originally designed for negative (or sometimes also for overall) but not affective symptoms. This uncertainty possibly contributes to the heterogeneity of results obtained in different studies and makes a between-study comparison difficult.

Antidepressants in the Treatment of Negative Symptoms of Schizophrenia {#s11}
----------------------------------------------------------------------

Only 5 of 14 RCTs with SSRIs reported favorable results. This puts into question the efficacy of this antidepressant group in the treatment of schizophrenia's negative symptoms. From a theoretical viewpoint, these findings possibly indicate that the increase of serotonin availability in the brain per se is not enough to alleviate the negative symptoms.

The data on selective serotonin and noradrenaline reuptake inhibitor (SNRIs) are scarce. Only one small study (with duloxetine) is available. Its desirable result needs further validation in larger studies. Studies with other SNRIs are also necessary.

For the TCAs, even though 2 of the 3 existing studies were positive, the small number of trials and methodological issues (omitted report on outcome measures or use of psychiatric scales with questionable reliability) makes the significance of these results uncertain.

In both available studies with reboxetine and bupropion, the active drug was not more efficacious than placebo, indicating that catecholamine reuptake inhibition alone is seemingly insufficient to alleviate negative symptoms of schizophrenia.

Data on the receptor-blocking antidepressants are more convincing, since they outperformed placebo in 10 of the 13 reported RCTs. This advantage may plausibly be interpreted with the dissimilar pharmacodynamic mechanisms of action of these compounds. While not affecting monoamine transporters (and thus reuptake of monoamines), all receptor-blocking antidepressants inhibit the postsynaptic serotonin 5HT2 receptors, a property that they share with clozapine and other SGAs ([@CIT0044]). The theory of atypicality, especially popular in the late 1990s, postulates that antipsychotics with higher affinity to the 5HT2 than to the dopamine D2 receptors (the atypical antipsychotics, or SGAs) were more effective in treating positive and negative symptoms and cognitive deficits and less prone to cause extrapyramidal side-effects compared with the FGAs, potent dopamine D2 blockers with low or negligible 5HT2 receptor inhibition ([@CIT0045]). The rationale for the use of the receptor-blocking antidepressants in schizophrenia is the presumption that combination of an inhibitor of the 5HT2 receptor (antidepressant) with a relatively pure D2 blocker (FGA) would result in a clinical effect resembling that of the SGAs, with possible additional benefits in terms of efficacy and tolerability ([@CIT0006]; [@CIT0034]). Preliminary evidence for this presumption was gained in a study by [@CIT0019] in which add-on ritanserin, a pure 5HT2 blocker devoid of antidepressive properties, improved negative symptoms in haloperidol-treated schizophrenia patients.

On the other hand, in 4 of 6 positive studies, mirtazapine was added to risperidone, clozapine, or olanzapine --each of them known to be a potent 5HT2A/C blocker by itself, which makes little sense from the viewpoint of the above-mentioned atypicality theory. A possible explanation for this advantageous effect may be the affinity of mirtazapine to some other (than 5HT2) types of receptors. In addition to the 5HT2 receptors, mirtazapine inhibits the postsynaptic serotonin 5HT3 receptors and presynaptic noradrenaline α2 receptors and indirectly stimulates postsynaptic serotonin 5HT1A receptors ([@CIT0015]), all of these believed to be involved in the pathophysiology of schizophrenia. Antagonists of the 5HT3 receptors seem potentially beneficial in the treatment of schizophrenia ([@CIT0014]). In a preclinical study by [@CIT0053], a 5HT3 receptor antagonist, itasetron, demonstrated procognitive effects, and in a clinical trial by [@CIT0084], another 5HT3 antagonist, ondansetron, was added to an on-going treatment with haloperidol and improved negative symptoms, general psychopathology, and cognitive functions in patients with schizophrenia.

Blockade of the noradrenaline α2 receptors also may be useful in the treatment of schizophrenia. In an RCT by [@CIT0042], the α2 antagonist idazoxan added to fluphenazine produced clinical improvement comparable with that of clozapine. This finding was later supported by 2 preclinical studies. [@CIT0079] found idazoxan to potentiate the antipsychotic-like effect of both FGA (haloperidol) and SGA (olanzapine) and also to reverse haloperidol-induced catalepsy in the laboratory animals. In another preclinical study, [@CIT0043] reported that adjunctive idazoxan had improved the efficacy of risperidone and facilitated cortical dopaminergic and glutamatergic neurotransmission.

Rummel et al. (2005) performed a systematic review of 5 RCTs (comprising the TCAs, receptor-blocking antidepressants, and SSRIs) available at that time and fulfilling the rigorous systematic review criteria. The authors concluded that "the combination of antipsychotics and antidepressants may be more effective in treating negative symptoms of schizophrenia than antipsychotics alone." This conclusion, although not differentiating between effects of different antidepressant subgroups, is mainly in line with that of the current review.

The efficacy of add-on antidepressants on negative symptoms of schizophrenia was reviewed by [@CIT0066]. Based on an analysis of 23 RCTs (n = 819), the authors found that add-on treatment with antidepressants was more effective for negative symptoms in chronic schizophrenia than monotherapy with antipsychotics. In particular, Singh and collaborators concluded that fluoxetine, trazodone, and ritanserin were the most efficient antidepressants for treating negative symptoms, while the majority of other antidepressants did not express such advantages compared with placebo. These findings seem to be controversial, especially for fluoxetine, which has been unable to outperform placebo in 3 of 5 studies published to date. Unlike [@CIT0066], we have found that data supporting clinical efficacy of add-on antidepressants on negative symptoms is most consistent for the receptor-blocking antidepressants. This difference in the results may be partly explained by the different number of studies included in these 2 reviews (9 RCTs on receptor-blocking antidepressants in the review by Singh and co-authors vs 13 RCTs in the current review). Some of the RCTs with receptor-blocking antidepressants ([@CIT0001]; [@CIT0074]; [@CIT0012]; [@CIT0010]) were not available at the time of preparation of the review by Singh and co-authors. Furthermore, the discrepancy could result from different methodology employed by Singh and co-authors, who based their conclusions on the computation of the effect size for each antidepressant separately.

[@CIT0020] did not find in their review any RCT data on improved negative symptoms with adjunctive bupropion.

Antidepressants in the Treatment of Positive Symptoms of Schizophrenia {#s12}
----------------------------------------------------------------------

Antidepressants seem to have no desirable effect on positive symptoms of schizophrenia, as almost all RCTs were disappointing in this respect. The only exception was a study by [@CIT0034], in which mirtazapine (but not placebo) added to on-going therapy with various FGAs improved positive symptoms. This result diverged from other mirtazapine trials. It is possible that in that particular study, the researchers succeeded in minimizing the regression to the mean by a sound process of stabilization of clinical status and dosage of the FGAs. Also, placebo response and low adherence to the protocol procedures were minimized by a placebo run-in period, which probably explained the high patient retention level. Stabilization and low drop-out rate might permit for surfacing a possible additive antipsychotic effect of mirtazapine. This observation, however, has to be replicated in other studies with similarly rigorous methodology.

In clinical practice, physicians are sometimes concerned with a risk of worsening or exacerbation of psychosis when prescribing antidepressants to patients with schizophrenia ([@CIT0052]). Moreover, some current schizophrenia treatment guidelines suggest caution when using antidepressants ([@CIT0003]). This review does not support this opinion, since not a single study with an add-on antidepressant reported worsening of positive symptoms. The majority of the presented RCTs, however, involved subjects with chronic schizophrenia, with only 3 trials comprising acutely ill subjects. It therefore remains unclear to what extent this observation can be extrapolated to acute schizophrenia.

Antidepressants in the Treatment of Depressive Symptoms of Schizophrenia {#s13}
------------------------------------------------------------------------

Only 2 of 6 studies with SSRIs were positive, and exactly the same proportion (2 of 6) was found with regard to receptor-blocking antidepressants. This puts the efficacy of both antidepressant groups into question. The antidepressants with sound noradrenaline activity may, however, be of interest for this symptom domain, since 1 of the 2 existing RCTs with reboxetine, the only study with imipramine, and the only study with duloxetine (compounds with a pronounced noradrenaline enhancing effect) reported improved depression. A trend in favor of active compound over placebo was observed in 1 of 2 RCTs with adjunctive noradrenaline and dopamine inhibitor bupropion. Of the 6 published trials with the receptor-blocking antidepressants, only one ([@CIT0073]) reported improved depression with add-on mirtazapine.

To summarize, the evidence regarding the efficacy of antidepressants in the treatment of depression in schizophrenia is scarce and controversial. The main methodological issue in this area is that the study population was not selected specifically for depressive symptoms, with the only exception of the postpsychotic depression study by [@CIT0067]. In the rest of the studies, change in depression scores was a subject for a secondary analysis.

Also, [@CIT0082] in their Cochrane review concluded that, although antidepressants may be of some benefit for people with depression and schizophrenia, the evidence was still far from convincing. The authors of that review also emphasized poor quality of the available literature as a contributing factor for this uncertainty.

Antidepressants in the Treatment of Extrapyramidal Side-Effects of Antipsychotics {#s14}
---------------------------------------------------------------------------------

For the monoamine transporter inhibitors, only SSRIs and the noradrenaline reuptake inhibitor reboxetine studies were identified. All these studies were negative, probably not surprisingly given the lack of theoretical basis for such combination in EPS. Moreover, the SSRIs are reported to even cause EPS in patients with major depressive disorder ([@CIT0026]).

For the receptor-blocking antidepressants, a positive effect on the FGA-induced EPS was found in both studies with trazodone ([@CIT0028]; [@CIT0074]) but in neither of the mianserin studies ([@CIT0028]; [@CIT0056]). Also, 4 of 5 studies with mirtazapine ([@CIT0006], [@CIT0007]; [@CIT0001]; [@CIT0012]) were negative. Nefazodone was found to improve haloperidol-induced Parkinsonism but not akathisia or tardive dyskinesia ([@CIT0083]).

The use of receptor-blocking antidepressants for the EPS arises from the theoretical assumption of dopamine insufficiency in the basal ganglia as the cause of EPS ([@CIT0076]). Inhibition of the 5HT2A/C receptors---a common pharmacological effect of SGAs and receptor-blocking antidepressants---may increase availability of dopamine in this area, thereby alleviating EPS. Another possible mechanism of alleviating antipsychotic-induced EPS by some of the receptor-blocking antidepressants may be an indirect stimulation of the serotonin 5HT1A receptors that leads to decrease of serotonin at 5HT2C receptors located on dopaminergic neurons ([@CIT0027]).

In sum, despite encouraging theoretical presumptions, the evidence regarding the efficacy of receptor-blocking antidepressants for antipsychotic-induced EPS is limited and contradictory. Only trazodone and nefazodone were found effective, while mianserin and mirtazapine were probably not. As marketing of nefazodone has been discontinued, the nefazodone-related findings are no longer relevant for clinical practice. Moreover, positive findings with receptor-blocking antidepressants are available for only FGA-induced EPS and may be extrapolated on the SGAs only with caution. Given that the use of FGAs has been markedly diminished during recent years and further decrease may happen in the future, the results of these studies are rather of theoretical than of practical interest.

Antidepressants in the Treatment of Cognitive Deficits Related to Schizophrenia {#s15}
-------------------------------------------------------------------------------

Neurocognitive effects of antidepressants added to antipsychotics in schizophrenia have been studied in only 3 RCTs.

A serotonin reuptake inhibitor, citalopram, did not improve cognition in schizophrenia ([@CIT0024]). The increase of availability of serotonin alone in the brain may not therefore improve neurocognition.

[@CIT0022] reported improved attention in patients with schizophrenia treated with bupropion for smoking cessation. This positive change became significant only after controlling for abstinence status. The influence of nicotine use and smoking cessation on cognitive performance in this study makes the results difficult to interpret.

On the contrary, 2 receptor-blocking antidepressants with a similar mechanism of action, mianserin ([@CIT0056]) and mirtazapine ([@CIT0072], [@CIT0073]), did improve neurocognition in FGA-treated schizophrenia patients.

As for the negative symptoms, the plausible proneurocognitive effect of mirtazapine and mianserin in schizophrenia may emerge from their receptor-binding profile. First, they may enhance prefrontal catecholamine activity via 5HT2A or 5HT2C receptor blockade (as most SGAs do), thereby enhancing activity of the prefrontal cortex ([@CIT0041]; [@CIT0047]). Second, the 5HT3 receptor modulation by mianserin or mirtazapine could improve neurocognition ([@CIT0002]) through increased release of acetylcholine ([@CIT0051]). Third, mirtazapine might improve neurocognition as a result of the indirect agonism of 5HT1A receptors ([@CIT0075]). Fourth, mianserin and mirtazapine inhibit the noradrenergic α2 receptors. Inhibition of the α2 receptors can enhance neurocognition via noradrenaline-mediated modulation of response to environmental stimuli ([@CIT0023]). Furthermore, the α2 receptor antagonism seems to boost hippocampal neurogenesis ([@CIT0057]). Mirtazapine is an even more potent α2 antagonist than clozapine, which may explain its additional neurocognition-enhancing effect even if added to clozapine, as demonstrated in an open label trial by [@CIT0017]. Mirtazapine may also boost the levels of the Brain-Derived Neurotrophic Factor ([@CIT0060]), a major mediator of neurogenesis and neuroplasticity, which are often abnormal in patients with schizophrenia ([@CIT0058]).

[@CIT0078] found in their meta-analysis clinically negligible (although statistically significant) improvement of neurocognitive functions with adjuvant antidepressants. However, while Vernon and colleagues analyzed pooled antidepressants, in the current review, each antidepressant study has been given separately.

The number of studies presented in both reviews was small. Thus, the evidence for the proneurocognitive potential of add-on antidepressants is, so far, insufficient but deserves further research.

Limitations {#s16}
-----------

The RCT is the gold standard of clinical efficacy studies. However, RCTs are fraught with patient selection bias and, thus, the results of available naturalistic prospective studies, mirror design studies, as well as pertinent register studies should be taken into account for balanced clinical decisions. Furthermore, we have not performed quantitative analyses of the data nor included unpublished data as it would be required for a systematic meta-analysis. Moreover, the vast majority of the available RCTs are small and methodologically heterogenic, which calls for caution when interpreting our results. In a substantial part of the RCTs in this review, the reported outcomes were a result of secondary analysis.

This review has focused predominantly on the efficacy of adjunctive antidepressants, while in clinical practice the potential benefits should be balanced against unwanted side-effects of these drugs and of antidepressant-antipsychotic combinations.

Further Directions {#s17}
------------------

In the future, well-designed, larger, and longer RCTs are needed. There is also a need for trials designed specifically for certain symptom domains, with appropriately selected patients and pertinent rating scales. Despite an existing theoretical rationale, there is a lack of studies assessing the effects of bupropion, reboxetine, SNRIs, and reversible inhibitors of monoamine oxidase A on cognitive function in schizophrenia.

The future studies should also focus on new, novel, add-on antidepressants that have come into clinical practice in recent years. Of interest may be, for instance, vortioxetine. In addition to the conventional inhibition of the serotonin (5HT) transporter, vortioxetine demonstrates an affinity to the serotonin 5HT1a, 5HT1b, 5HT1d, 5HT3, and 5HT7 receptors. Furthermore, it modulates the GABA, MNDA, noradrenergic, dopaminergic, cholinergic, and histaminergic neurotransmitter systems ([@CIT0039]; [@CIT0071]). Some of these receptors and neurotransmitters may be involved in pathophysiology of schizophrenia. In addition to the symptoms of depression, vortioxetine may improve cognitive functions in patients with major depressive disorder ([@CIT0069]).

[List of RCTs]{.smallcaps}: {#s19}
===========================

1.  [@CIT0013]

2.  [@CIT0080]

3.  [@CIT0018]

4.  [@CIT0068]

5.  [@CIT0064]

6.  [@CIT0016]

7.  [@CIT0070]

8.  [@CIT0025]

9.  [@CIT0008]

10. [@CIT0061]

11. [@CIT0028](a)

12. [@CIT0028](b)

13. [@CIT0037]

14. [@CIT0004]

15. [@CIT0065]

16. [@CIT0006]

17. [@CIT0062]

18. [@CIT0054]

19. [@CIT0063]

20. [@CIT0009]

21. [@CIT0049]

22. [@CIT0055]

23. [@CIT0056]

24. [@CIT0083]

25. [@CIT0087]

26. [@CIT0021](a)

27. [@CIT0021](b)

28. [@CIT0024]

29. [@CIT0033]

30. [@CIT0007]

31. [@CIT0034]

32. [@CIT0001]

33. [@CIT0072]

34. [@CIT0074]

35. [@CIT0031]

36. [@CIT0012]

37. [@CIT0012]

38. [@CIT0048]

39. [@CIT0073]

40. [@CIT0081]

41. [@CIT0010]

Conclusions {#s18}
===========

There exists a substantial number of RCTs on the efficacy of add-on antidepressants, but due to methodological issues the results remain uncertain. Receptor-blocking antidepressants mirtazapine and mianserin show somewhat consistent efficaciousness for negative symptoms. The evidence for EPS, neurocognition, and depression domains is even more ambiguous and should be interpreted with caution. Some receptor-blocking antidepressants (trazodone and nefazodone) seem to improve FGA-induced EPS, while others (mirtazapine and mianserin) appear to enhance neurocognition. Transporter-blocking antidepressants with prominent noradrenergic activity tended to improve depressive symptoms.

The overall data for the SSRIs are rather disappointing. An add-on antidepressant (mirtazapine) improved positive symptoms in only one study. However, the data unequivocally show that adjunctive antidepressants do not worsen psychosis, at least in chronic schizophrenia. The caution recommended for antidepressants in some current schizophrenia treatment guidelines may, therefore, need reappraisal.

Interest Statement
==================

None.
